StockData
Nasus Pharma Ltd logo

Nasus Pharma Ltd (NSRX) stock

NSRXNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Mar 25, 2026Score 6/30
$2.87+0.05 (+1.77%)

Close on Nov 13, 2026Market cap $25.87MP/E –Yield –

Nasus Pharma r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was $2.24M, up 567.8% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$2.24M+567.8%
FY2024Dec 31, 2024$335.00K-40.9%
FY2023Dec 31, 2023$567.00K–

More Nasus Pharma figures

See a number that looks wrong?